--- title: "Verrica Pharmaceuticals (VRCA) news: reverse split" url: "https://aibio.space/companies/verrica-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "VRCA reverse split, class action, going concern, offering and settlement news: Verrica Pharmaceuticals details 1-for-10 reverse split and $8.0 million Torii…" --- VRCA Verrica Pharmaceuticals Inc. NASDAQ · United States # Verrica Pharmaceuticals (VRCA) news VRCA reverse split, class action and going concern news Legal · 2026-08-06 ## [Verrica agrees in principle to settle 2022 securities class action over YCANTH](https://aibio.space/news/verrica-agrees-principle-settle-2022-securities-class-action-ycanth/) Defendants: Verrica and unnamed current and former officers and directors. A July term sheet would end a case certified in March; Verrica accrued $4.0 million and needs court approval. ## Latest Verrica Pharmaceuticals news 1. 2025-11-24 Financings [Verrica Pharmaceuticals agrees to about $50 million private placement to retire OrbiMed debt](https://aibio.space/news/verrica-pharmaceuticals-agrees-about-50-million-private-placement/) Verrica agreed to sell common stock, pre-funded warrants and Series C warrants for about $50 million, and will use $35.0 million to settle its OrbiMed credit agreement. The company says cash will last into mid-2027. 2. 2025-08-12 Listings [Verrica Pharmaceuticals details 1-for-10 reverse split and $8.0 million Torii milestone](https://aibio.space/news/verrica-pharmaceuticals-details-1-10-reverse-split-8-0-million-torii/) Verrica's 1-for-10 reverse stock split took effect at the close of trading on July 24, 2025, cutting issued shares from 92,650,404 to 9,265,034. Second-quarter net income of $0.2 million depended on an $8.0 million Torii milestone. 3. 2024-11-20 Financings [Verrica Pharmaceuticals prices $42,007,776 stock and warrant offering at $0.89](https://aibio.space/news/verrica-pharmaceuticals-prices-42-007-776-stock-warrant-offering-0-89/) Verrica priced 44,964,045 shares at $0.89 with Series A and B warrants, for a total public offering price of $42,007,776. Entities tied to director Paul B. Manning agreed to buy 22.9 million shares, and the filing carries a going-concern warning. ## Verrica Pharmaceuticals at a glance - **Ticker**: VRCA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $11.2 million ### Related companies - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) NASDAQ: MGRX - [Accustem Sciences](https://aibio.space/companies/accustem-sciences/) OTC: ACUT - [Alzamend Neuro](https://aibio.space/companies/alzamend-neuro/) NASDAQ: ALZN - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [Avalo Therapeutics](https://aibio.space/companies/avalo-therapeutics/) NASDAQ: AVTX - [Inhibitor Therapeutics](https://aibio.space/companies/inhibitor-therapeutics/) OTC: INTI - [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) NASDAQ: TGTX - [Rafarma Pharmaceuticals, Inc. (WY)](https://aibio.space/companies/rafarma-pharmaceuticals-wy/) OTC: RAFA ### Also on NASDAQ - [Equillium](https://aibio.space/companies/equillium/) EQ - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) RLAY - [Telomir Pharmaceuticals](https://aibio.space/companies/telomir-pharmaceuticals/) TELO - [InMode](https://aibio.space/companies/inmode/) INMD - [QuidelOrtho](https://aibio.space/companies/quidelortho/) QDEL - [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) ZVRA ## What Verrica Pharmaceuticals does Verrica Pharmaceuticals Inc. is a therapeutics company developing and commercializing medications for dermatologic diseases, including skin cancers. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. The FDA approved YCANTH in July 2023 for the treatment of molluscum in adult and pediatric patients two years of age and older, and the company launched it in August 2023. It has built a specialized sales organization of approximately 40 field employee sales representatives as of December 31, 2025, focused on dermatologists, pediatric dermatologists, pediatricians and select other primary care providers. The company is also developing YCANTH for a potential follow-on indication for common warts. Its second development candidate, VP-315 (ruxotemitide), is an oncolytic peptide-based injectable therapy for dermatology oncologic conditions, including basal cell carcinoma. | Product or program | What it is | Stage | |---|---|---| | YCANTH (VP-102) | Cantharidin drug-device combination for molluscum in patients two years and older | approved in the US | | YCANTH for common warts | Potential follow-on indication for the treatment of common warts | in development | | VP-315 (ruxotemitide) | Oncolytic peptide-based injectable therapy for basal cell carcinoma | in development | Summarised from the company's [10-K filed Mar 11, 2026](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm). ## Verrica Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$35.6 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | [$7.6 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | | Research and development | [$8.9 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | [$11.8 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | | Net income (loss) | [-$17.9 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | [-$76.6 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | | Cash from operations | [-$17.6 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | [-$60.9 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | | Cash and equivalents | [$30.1 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000025/) | [$46.3 million](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $11.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Verrica Pharmaceuticals Did Verrica Pharmaceuticals do a reverse stock split? Our latest story on this, dated Aug 12, 2025: "Verrica Pharmaceuticals details 1-for-10 reverse split and $8.0 million Torii milestone". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/verrica-pharmaceuticals-details-1-10-reverse-split-8-0-million-torii/). Is there a class action against Verrica Pharmaceuticals? Our latest story on this, dated Aug 6, 2026: "Verrica agrees in principle to settle 2022 securities class action over YCANTH". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/verrica-agrees-principle-settle-2022-securities-class-action-ycanth/). Has Verrica Pharmaceuticals issued a going-concern warning? Our latest story on this, dated Nov 20, 2024: "Verrica Pharmaceuticals prices $42,007,776 stock and warrant offering at $0.89". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/verrica-pharmaceuticals-prices-42-007-776-stock-warrant-offering-0-89/). Has Verrica Pharmaceuticals raised money recently? Our latest story on this, dated Nov 24, 2025: "Verrica Pharmaceuticals agrees to about $50 million private placement to retire OrbiMed debt". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/verrica-pharmaceuticals-agrees-about-50-million-private-placement/). Has Verrica Pharmaceuticals settled a lawsuit? Our latest story on this, dated Aug 6, 2026: "Verrica agrees in principle to settle 2022 securities class action over YCANTH". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/verrica-agrees-principle-settle-2022-securities-class-action-ycanth/). What is the ticker symbol of Verrica Pharmaceuticals? Verrica Pharmaceuticals Inc. trades under the ticker VRCA on NASDAQ. Where is Verrica Pharmaceuticals listed? Verrica Pharmaceuticals Inc. is listed on NASDAQ. Our directory also records these other listings: LS:A41A98. What is the SEC CIK of Verrica Pharmaceuticals? The SEC Central Index Key (CIK) for Verrica Pharmaceuticals Inc. is 1660334. Its filings are on SEC EDGAR. How many shares does Verrica Pharmaceuticals have outstanding? 17,178,786 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Verrica Pharmaceuticals listed under? Our directory records Verrica Pharmaceuticals Inc. under United States. What does Verrica Pharmaceuticals do? Our directory classifies Verrica Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Verrica Pharmaceuticals? The ISIN recorded for Verrica Pharmaceuticals Inc. is US92511W2070. Does aibio.space cover Verrica Pharmaceuticals? aibio.space lists Verrica Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Verrica Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Verrica Pharmaceuticals develop? Verrica Pharmaceuticals Inc. is a therapeutics company developing and commercializing medications for dermatologic diseases, including skin cancers. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. ## Investor discussion: Verrica Pharmaceuticals Members talk about Verrica Pharmaceuticals (VRCA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Verrica Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-03-11 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm) 2. 2025-11-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312525292155/d692687dex991.htm) 3. 2025-08-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/d409147dex991.htm) 4. 2025-07-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312525169309/d62269d8k.htm) 5. 2025-07-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312525162939/d30630d8k.htm) 6. 2025-06-05 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312525135949/d82912d8k.htm) 7. 2025-04-22 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312525087838/d905798ddef14a.htm) 8. 2025-04-11 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312525079118/d905798dpre14a.htm) 9. 2025-03-11 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1660334/000095017025037172/vrca-20241231.htm) 10. 2025-01-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312525017264/d913894d8k.htm) 11. 2024-11-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1660334/000119312524262611/d817723d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VRCA on TradingView](https://www.tradingview.com/symbols/NASDAQ-VRCA/). ## SEC filings and registration - **SEC name**: Verrica Pharmaceuticals Inc. - **CIK**: 1660334 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: VRCA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 44 WEST GAY STREET, WEST CHESTER, PA - **Phone**: 484-453-3300 - **Shares outstanding**: 17,178,786 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000025/vrca-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828d8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/d139416d8k.htm) filed 2026-06-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000014/vrca-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529d8k.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1660334/000119312526163961/d61950ddef14a.htm) filed 2026-04-20 - [10-K](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm) filed 2026-03-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/d94203d8k.htm) filed 2026-03-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001660334), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Verrica Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VRCA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Verrica Pharmaceuticals Inc. - **Ticker**: VRCA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US92511W2070 - **Other listed symbols**: LS:A41A98 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VRCA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/verrica-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Verrica Pharmaceuticals (VRCA) news: reverse split", 2026-10-31, https://aibio.space/companies/verrica-pharmaceuticals/